Adriana G. Ioachimescu, MD, PhD, FACE Consulting Editor
Diabetes remission is a relatively new concept that reflects the advances in diabetes management. In 2021, experts defined it as achieving an improvement of HbA1c to 6.5% or less for at least 3 months and in absence of pharmacotherapy. This concept is multifaceted, with socioeconomic, educational, and pharmacologic implications. The underlying pathogenetic links depend on the diabetes type and treatment modalities. The authors discuss the effectiveness of various modalities that can result in type 2 diabetes remission, including lifestyle interventions, bariatric surgery, and medications. Also included in our issue is an update on the islet cell transplantation for patients with type 1 diabetes. Diabetes complications should be monitored in patients who attain the favorable outcome of near-normal glycemia. Our issue includes discussions about nephropathy, retinopathy, neuropathy, and foot ulcers.
Achieving remission is a worthwhile task that requires multidisciplinary collaboration between endocrinologists, internists, diabetes educators, surgeons, and other team members. The teamwork entails a long-term approach to care, so that, it is hoped, remission is maintained. The methodology is patient-centric, dependent on diabetes type, complications, and various other individual factors that may impact the disease course.
I hope you will find this issue of the Endocrinology and Metabolism Clinics of North America a great resource for your practice. I would like to thank Dr Hatipoglu, our guest editor, and the authors for their valuable contributions. As with every issue of the Endocrinology and Metabolism Clinics of North America, I am grateful to the Elsevier editorial staff for their continuous support.
Article info
Identification
Copyright
© 2022 Published by Elsevier Inc.
00108-6&id=fx1.jpg){kind=link}